Analysis of the use of cyclosporin A to treat refractory immune recurrent spontaneous abortion.
This study aims to determine the curative effect of cyclosporin A (CsA) in treating refractory immune recurrent spontaneous abortion (RSA). Patients with recurrent abortion caused by dysimmunity were enrolled. The patients were given aspirin, prednisone, heparin, immunotherapy with their husband's leukomonocyte, and intravenous immunoglobulin (IVIG) treatment, but treatment outcomes were unsuccessful. Therefore, CsA was added to treat the women before and after pregnancy. During treatment, CsA concentration was maintained at 80 ng/ml to 150 ng/ml. The clinical effect and pregnancy outcome were observed. Of the 26 patients, 20 cooperated and accomplished complete pregnancy. Twelve cases showed hypertensive disorders during pregnancy but did not exhibit symptoms of preeclampsia. Three cases were lost to follow-up. The success rate was 76.92%. Twenty patients underwent premature labor (34 weeks to 37 weeks). Nevertheless, the mothers and their children were all healthy. An appropriate dose of CsA has good curative effects and pregnancy results in the treatment of RSA.